Exploration of META HUNTER Bioresonance Wave Frequency for Diabetes

Diabetes Mellitus is an important medical issue at present. According to the latest statistics of the World Health Organization in 2017, among the total population of 7.5 billion in the world, more than 400 million people are suffering from the disease, accounting for about 5.3%. As far as a single disease is concerned, its prevalence rate is sufficient.

There are two main ways to treat diabetes at present: oral medication and insulin injection, which have serious side effects and are prone to liver and kidney failure. A new diabetes therapy with the characteristics of assisting in reducing medication, having few side effects, and not easily affecting liver and kidney function is a top priority and is also expected by the diabetes medical field.

In this study, we added a physical, non-invasive auxiliary medical device and technology called META HUNTER bioresonance waves (bRWs, biological Resonance waves). After basic cell and animal experiments and human clinical trials, it has been confirmed that its effectiveness has the potential to meet the current needs and applications in the medical field.

In the exploration of the frequency of bioresonance waves for diabetes, after scientific analysis and induction, the content that can relieve high blood sugar conditions has been studied for subsequent biomedical verification. This is a bottom-up study. First, HaCaT cells were used for in vitro experiments to understand the effect of META HUNTER resonance waves on the ability of mitochondria to regulate glucose, providing verification at the cellular level. Then, in the pre-clinical part, STZ-induced diabetic mice were used to compare the glycosylated hemoglobin (HbA1c) and oral glucose tolerance (OGTT) performance after the application of resonance wave therapy, providing in vivo safety and validity verification, and exploring possible mechanisms. Finally, after formal trial ethics and Ministry of Health and Welfare review, a 20-month human clinical trial was conducted at the Luodong St. Mary's Hospital in Yilan, with 72 cases, to actually verify the efficacy of this new medical auxiliary technology.